Clinical Trials Arena on MSN
Eli Lilly’s Ebglyss shows sustained skin clearance in atopic dermatitis trial
Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback